Chemistry:Edrecolomab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | EpCAM (17-1A) |
| Clinical data | |
| Trade names | Panorex |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).[1][2] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[3]
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.
References
- ↑ "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group". Lancet 343 (8907): 1177–83. May 1994. doi:10.1016/s0140-6736(94)92398-1. PMID 7909866.
- ↑ "Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study". Lancet 360 (9334): 671–7. August 2002. doi:10.1016/S0140-6736(02)09836-7. PMID 12241873.
- ↑ "Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)". Journal of Clinical Oncology 22 (14_suppl): 3522. July 2004. doi:10.1200/jco.2004.22.90140.3522.
 |  |
